Paper 09 - DEMOGRAPHICS, PROGNOSIS FACTORS, AND OUTCOMES FOR PATIENTS (PTS) WITH #SARCOMA AND #COVID19: A CCC19-REGISTRY BASED RETROSPECTIVE COHORT ANALYSIS @CTOS Michael Wagner Elizabeth Davis Vivek Subbiah, MD Emily Jonczak, MD cdmcd.co/Wk33Jy #CTOS2021

Promising data - looking forward to next step with this combo

Development of sodium fluoride PET response criteria for solid tumours (NAFCIST) in a clinical trial of radium-223 in osteosarcoma: from RECIST to PERCIST to NAFCIST ESMO - Eur. Oncology ESMO Open OncoAlert esmoopen.com/article/S2059-…

The amazing Christina Wu from Mayo Clinic Comprehensive Cancer Center putting all things #colorectalcancer ASCO in perspective! Kristen Ciombor Daniel Ahn Alan H Bryce

🚨 KEYNOTE-564 is the FIRST positive study for adjuvant #immunotherapy in renal cell carcinoma. ✅Amazing work published in The Lancet Oncology by Toni Choueiri, MD & colleagues 👏🏼 OncoAlert

New SCCT Expert Consensus co-endorsed by International Cardio-Oncology Society: #YesCCT in Cardio-Oncology This document fills existing gaps about CCT in Cardio-Oncology w experts in cardio-oncology, CCT imaging and cancer medicine Journal of Cardiovascular CT 👉bit.ly/3UlOMGr Juan Lopez-Mattei, MD Maros Ferencik

Hyperprogression and Immunotherapy: Fact, Fiction, or Alternative Fact? cell.com/trends/cancer/…

Molecular pathogenesis of desmoid tumor and the role of γ-secretase inhibition | npj Precision Oncology nature.com/articles/s4169…

⭐️The burden of bureaucracy in clinical research is overwhelming investigators & clinical research teams. This ESMO - Eur. Oncology manuscript proposes a framework of principles to improve Sponsoring & Monitoring of Clinical Trials Annals of Oncology OncoAlert annalsofoncology.org/article/S0923-…

Expanding biomarkers for PARP inhibitors | Nature Cancer nature.com/articles/s4301…

Clinical Development of BRAF plus MEK Inhibitor Combinations Trends in Cancer cell.com/trends/cancer/…

☀️The science news cycle #FridayThoughts PHD Comics

IN THE NEWS | Nivolumab resulted in significant antitumor activity, prolonged responses and a good tolerability in patients with advanced cutaneous squamous-cell carcinoma in the first-line setting. acsjournals.onlinelibrary.wiley.com/doi/full/10.10… Vivek Subbiah, MD OncoAlert

🚨🥁Hot off the press just in time for National Cancer Institute EORTC AACR #ENASymp22 ! 👉🏼Drugging KRAS -current perspectives & state-of-art review ➡️Many 🎯drugs targeting KRAS @Oncoalert jhoonline.biomedcentral.com/articles/10.11…

Great work by ⁦Danh Truong, PhD⁩ highlighting subtypes of DSRCT presented ⁦CTOS⁩ #CTOS2022 Need better therapy. Opportunity for future trial?

Amazing talk and most well deserved recognition for #sarcoma #superstar #spectacular #womaninsarcoma Inga-Marie Schaefer #CTOSTweeTOS !!!

⭐️It's Friday & we have another approval !!! FDA Approves Atezolizumab for Alveolar Soft Part Sarcoma. It is the 1st #Immunotherapy approval specifically for a sarcoma subtype ! OncoAlert onclive.com/view/fda-appro… via @onclive

Amazing...

Amazing angiosarcoma data by Dr. Grilley-Olson 👏🏻 Cabo+nivo with responses in cutaneous and non-cutaneous AS ⁦#sarcoma #ASCO23